Irinotecan and Radiation Therapy for Lung Cancer
Author Information
Author(s): Takeda K, Negoro S, Kudoh S, Okishio K, Masuda N, Takada M, Tanaka M, Nakajima T, Tada T, Fukuoka M
Primary Institution: Osaka City General Hospital
Hypothesis
The study aims to determine the maximum tolerated dose and response rate of irinotecan with concurrent radiation therapy in patients with locally advanced non-small cell lung cancer.
Conclusion
The combined therapy of irinotecan and radiation shows promising results with acceptable toxicity for patients with locally advanced non-small cell lung cancer.
Supporting Evidence
- The objective response rate was 76.9%.
- Severe oesophagitis, pneumonitis, and diarrhoea were observed as dose-limiting toxicities.
- Three of five patients at the highest dose developed severe oesophagitis and pneumonitis.
Takeaway
Doctors tested a new treatment for lung cancer using a medicine called irinotecan and radiation, and it worked well for many patients without causing too many bad side effects.
Methodology
Patients received weekly irinotecan infusions for 6 weeks alongside radiation therapy, with dose escalation to determine maximum tolerated doses.
Limitations
The study had a small sample size and focused only on specific stages of lung cancer.
Participant Demographics
Patients with histologically documented, surgically unresectable stage IIIA or IIIB non-small cell lung cancer.
Statistical Information
Confidence Interval
95% CI, 53.0–88.9%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website